Tryngolza (olezarsen) is the first approved therapy to significantly lower acute pancreatitis events alongside robust triglyceride reductions in adults with severe hypertriglyceridemia.

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

The novel topical gel, designed to clear mutant keratin aggregates and restore intermediate filament network integrity via autophagy, is undergoing evaluation in the phase 2 TAMES-02 trial.

The FDA wants to remove a limitation stating that the therapy's safety and effectiveness have not been established in men with age-related low testosterone ...

Saliency-based score highlighted biologically meaningful regions, especially the optic nerve head and retinal vasculature.